# TCR-engineered T Cells in Solid Tumors: IMA202-101

> **NCT03441100** · PHASE1 · COMPLETED · sponsor: **Immatics US, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumor, Adult
- Refractory Cancer
- Recurrent Cancer
- Cancer

## Interventions

- **DRUG:** IMA202 Product
- **DEVICE:** IMADetect®

## Key facts

- **NCT ID:** NCT03441100
- **Lead sponsor:** Immatics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2022-06-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441100, "TCR-engineered T Cells in Solid Tumors: IMA202-101". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03441100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*